VictorSandorMDFRCPC

PubMed

• 203 citations
  Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With...
  Herbert Hurwitz, Nikhil Uppal, Stephanie Ann Wagner, Johanna C. Bendell, J. Thaddeus Beck, Seaborn M. Wade, John Nemunaitis, Philip J. Stella, J. Marc Pipas, Zev A. Wa...> ;Journal of Clinical Oncology. 2015 Sep 8
• 184 citations
  A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
  Alessandro M. Vannucchi, Hagop M. Kantarjian, Jean-Jacques Kiladjian, Jason Gotlib, Francisco Cervantes, Ruben A. Mesa, Nicholas J. Sarlis, Wei Peng, Victor Sandor, Pr...> ;Haematologica. 2015 Sep 1
• 57 citations
  Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with Myelofibrosis from COMFORT-I
  Ruben A. Mesa, Srdan Verstovsek, Vikas Gupta, John Mascarenhas, Ehab Atallah, Timothy Burn, William Sun, Victor Sandor, Jason Gotlib> ;Clinical Lymphoma, Myeloma & Leukemia. 2015 Apr 1
• Three-year efficacy, overall survival, and safety of ruxolitinib therapy in patients with myelofibrosis from the COMFORT-I study.
  Verstovsek, S.,Mesa, R. A.,Gotlib, J.,Levy, R. S.,Gupta, V.,DiPersio, J. F.,Catalano, J. V.,Deininger, M. W.,Miller, C. B.,Silver, R. T.,Talpaz, M.,Winton, E. F.,Harve...> ;Haematologica. 2015 Jan 27
• 132 citations
  A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
  Srdan Verstovsek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Peter Rosen, Elisa Rumi, Elisabetta Gattoni, Lisa Pieri, Paola Guglielmelli, Chiara Elena...> ;Cancer. 2014 Feb 15
• 33 citations
  Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies
  Ruben A. Mesa, Jean-Jacques Kiladjian, Srdan Verstovsek, Haifa Kathrin Al-Ali, Jason Gotlib, Heinz Gisslinger, Richard S. Levy, Andres Siulnik, Vikas Gupta, Mahmudul K...> ;Haematologica. 2014 Feb 1
• 43 citations
  Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.
  Srdan Verstovsek, Alfonso Quintás-Cardama, Hagop M. Kantarjian, Jason Gotlib, Vikas Gupta, Ehab Atallah, John Mascarenhas, William Sun, Nicholas J. Sarlis, Victor Sand...> ;Oncotargets and Therapy. 2013 Dec 17
• Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
  Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MWN, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO...> ;Haematologica. 2013-12-01
• 81 citations
  Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
  Moshe Talpaz, Ronald Paquette, Lawrence B. Afrin, Solomon I. Hamburg, Josef T. Prchal, Katarzyna Jamieson, Howard R. Terebelo, Gregory L. Ortega, Roger M. Lyons, Ramon...> ;Journal of Hematology & Oncology. 2013 Oct 29
• 28 citations
  Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study
  Ruben A. Mesa, Alan L. Shields, Thomas Hare, Susan Erickson-Viitanen, William Sun, Nicholas J. Sarlis, Victor Sandor, Richard S. Levy, Srdan Verstovsek> ;Leukemia Research. 2013 Aug 1
• 27 citations
  Population Pharmacokinetic Analysis of Orally‐Administered Ruxolitinib (INCB018424 Phosphate) in Patients With Primary Myelofibrosis (PMF), Post‐Polycythemia Vera Myel...
  Xuejun Chen, William V. Williams, Victor Sandor, Swamy Yeleswaram> ;Journal of Clinical Pharmacology. 2013 Jul 1
• 75 citations
  The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
  Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver...> ;British Journal of Haematology. 2013 May 1
• 150 citations
  Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
  Ruben A. Mesa, Jason Gotlib, Vikas Gupta, John Catalano, Michael W. Deininger, Alan L. Shields, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, J...> ;Journal of Clinical Oncology. 2013 Apr 1
• 1424 citations
  A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
  Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver...> ;The New England Journal of Medicine. 2012 Mar 1
• RESPONSE: A randomized, open label, phase III study of INC424 in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU).
  Verstovsek S, Kiladjian J, Waltzman RJ, Sandor V, Lukawy J, Garrett WM, Malek K, Huber RM, Vannucchi AM> ;J. Clin. Oncol.. 2011-05-20
• Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF).
  Verstovsek S, Mesa RA, Gotlib JR, Levy RS, Gupta V, DiPersio JF, Catalano J, Deininger M, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Vaddi K, Erickson-Viita...> ;J. Clin. Oncol.. 2011-05-20
• 5 citations
  SarCNU, a Nitrosourea Analog on a Day 1, 5, and 9 Oral Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Tumors
  Lawrence Panasci, S.F. Stinson, David Melnychuk, Victor Sandor, Wilson H. Miller, Gerald Batist, Francois Patenaude, N. Bangash, L. Panarello, Moulay A. Alaoui-Jamali,...> ;Journal of Clinical Oncology. 2003 Jan 15
• 358 citations
  Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report
  Richard Piekarz, Rob Robey, Victor Sandor, Susan Bakke, Wyndham H. Wilson, Laila Dahmoush, Douglas M. Kingma, Maria L. Turner, Rosemary M. Altemus, Susan E. Bates> ;Blood. 2001 Nov 1
• 5 citations
  Bleomycin-Induced Lung Toxicity and Pentoxifylline
  John R. Goffin, Harvey Kreisman, Victor Sandor> ;Journal of Clinical Oncology. 2001 Jan 15
• 39 citations
  FR901228 causes mitotic arrest but does not alter microtubule polymerization.
  Victor Sandor, April R. Robbins, Rob Robey, Timothy G. Myers, Edward A. Sausville, Susan E. Bates, Dan L. Sackett> ;Anti-Cancer Drugs. 2000 Jul 1
• Clodronate in metastatic breast cancer.
  Panasci LC, Sandor V, Melnychuk D> ;N. Engl. J. Med.. 1998-12-24
• 45 citations
  Using the National Cancer Institute Anticancer Drug Screen to Assess the Effect of MRP Expression on Drug Sensitivity Profiles
  Manuel Alvarez, Robert W. Robey, Victor Sandor, K. Nishiyama, Yoshihito Matsumoto, Kenneth D. Paull, Susan E. Bates, Tito Fojo> ;Molecular Pharmacology. 1998 Nov 1
• 163 citations
  Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma.
  V Sandor, V Stark-Vancs, D Pearson, R Nussenblat, S M Whitcup, Pim Brouwers, Nicholas J. Patronas, John D. Heiss, Elaine S. Jaffe, M deSmet, David R. Kohler, Richard S...> ;Journal of Clinical Oncology. 1998 Sep 1
• 47 citations
  Future perspectives for the development of P-glycoprotein modulators
  Victor Sandor, Tito Fojo, Susan E. Bates> ;Drug Resistance Updates. 1998 Jan 1
• 20 citations
  The Role of MDR-1 in Refractory Lymphoma
  Victor Sandor, Wyndham H. Wilson, Tito Fojo, Susan E. Bates> ;Leukemia & Lymphoma. 1997 Dec 1
• Join now to see all